Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Jaffee

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
Human Molecular Genetics|August 9, 2022
Complement factor B is critical for sub-RPE deposit accumulation in a model of Doyne honeycomb retinal dystrophy with features of age-related macular degenerationMaura A Crowley, Donita L Garland, Holger Sellner, et al.
Molecular Therapy. Methods & Clinical Development|July 23, 2015
AAV-mediated RLBP1 gene therapy improves the rate of dark adaptation in Rlbp1 knockout miceVivian W Choi, Chad E Bigelow, Terri L McGee, et al.
Journal of Medicinal Chemistry|July 27, 2001
Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivoC B Xue, M E Voss, D J Nelson, et al.
Journal of Medicinal Chemistry|February 20, 2020
Discovery of 4-((2<i>S</i>,4<i>S</i>)-4-Ethoxy-1-((5-methoxy-7-methyl-1<i>H</i>-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated DiseasesNello Mainolfi, Takeru Ehara, Rajeshri G Karki, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
Human Molecular Genetics|August 9, 2022
Complement factor B is critical for sub-RPE deposit accumulation in a model of Doyne honeycomb retinal dystrophy with features of age-related macular degenerationMaura A Crowley, Donita L Garland, Holger Sellner, et al.
Molecular Therapy. Methods & Clinical Development|July 23, 2015
AAV-mediated RLBP1 gene therapy improves the rate of dark adaptation in Rlbp1 knockout miceVivian W Choi, Chad E Bigelow, Terri L McGee, et al.
Journal of Medicinal Chemistry|July 27, 2001
Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivoC B Xue, M E Voss, D J Nelson, et al.
Journal of Medicinal Chemistry|February 20, 2020
Discovery of 4-((2<i>S</i>,4<i>S</i>)-4-Ethoxy-1-((5-methoxy-7-methyl-1<i>H</i>-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated DiseasesNello Mainolfi, Takeru Ehara, Rajeshri G Karki, et al.
Pageof 6